| Old Articles: <Older 8971-8980 Newer> |
|---|
 |
Fast Company
Sarah Kessler |
Why There Is No Available Ebola Vaccine Ebola has the unprofitable qualities of being both relatively rare and infecting a mostly poor population. No pharma company wanted to foot the bill for human trials and production.   |
Chemistry World
October 23, 2014
Rebecca Trager |
Amgen seeks injunction to protect patents The US biopharmaceutical company Amgen has filed a patent infringement lawsuit against Sanofi and Regeneron in the US District Court of Delaware. |
Chemistry World
October 23, 2014
Rebecca Trager |
US agency fast-tracks Ebola vaccine development The US Department of Health and Human Services is fast-tracking tests on an Ebola vaccine by providing $5.8 million under a one-year contract with the Maryland-based biotech company Profectus BioSciences |
Information Today
October 23, 2014 |
Elsevier Offers Medical Reference Digests The series uses updated content from Elsevier's Clinics Review Articles database that is targeted to specific practice areas such as asthma, obesity, and pain management. |
Chemistry World
October 17, 2014
Phillip Broadwith |
AbbVie backs out of Shire deal AbbVie has recommended its shareholders vote against the deal, and if that happens, the company will pay Shire a break-off fee of $1.6 billion. |
Chemistry World
October 17, 2014
Dinsa Sachan |
Indian manufacturers hit back over quality claims The Indian pharmaceutical industry has asked its government to sue authors of a study published by the US National Bureau of Economic Research in early September. |
Chemistry World
October 16, 2014
Rebecca Trager |
Cannabis chemists look for professional recognition The American Chemical Society is being petitioned to create a professional division for cannabis chemists to serve the needs of analytical chemists in the cannabis industry. |
Pharmaceutical Executive
October 1, 2014
Leela Barham |
The Gate Keeper Dr. David Haslam, Chair of the UK's National Institute of Health and Care Excellence, discusses what the quantitative calculations of value mean to patient access in today's messy world of real-time medicine. |
Pharmaceutical Executive
October 1, 2014 |
Dealmaking: Staying Ahead of the Curve Amid the continued surge in M&A activity, Michael Swanick asks, what are the crucial considerations pharma executives should weigh before sitting down at the deals table? |
Pharmaceutical Executive
October 1, 2014
William Looney |
IDEAlogue for Innovation Professor Fabio Pammolli, a leading European economist and policy advisor to the key EU institutions, outlines the current dilemma facing health and pharma regulators in Europe today. |
| <Older 8971-8980 Newer> Return to current articles. |
